Description
Aspirin Gastro-Resistant & Rosuvastatin Capsules IP are a fixed-dose combination used for the prevention of cardiovascular events in patients with established or high-risk atherosclerotic cardiovascular disease (ASCVD). This combination addresses two key aspects of cardiovascular risk: platelet aggregation and lipid control.
- Aspirin, in a gastro-resistant form, acts as an antiplatelet agent. It irreversibly inhibits cyclooxygenase-1 (COX-1), reducing thromboxane A₂ production and preventing platelet activation and aggregation. The enteric coating minimizes gastric irritation and protects the stomach lining.
- Rosuvastatin is a high-potency HMG-CoA reductase inhibitor (statin) that reduces LDL cholesterol and triglycerides while modestly increasing HDL cholesterol. It also offers anti-inflammatory and plaque-stabilizing effects.
Together, they provide dual cardiovascular protection by reducing the risk of heart attack, stroke, and other thrombotic events, especially in patients with dyslipidemia and a history of coronary artery disease.
Mechanism of Action:
- Aspirin irreversibly inhibits platelet COX-1, blocking thromboxane A2 synthesis, which prevents clot formation.
- Rosuvastatin inhibits the HMG-CoA reductase enzyme, lowering cholesterol production in the liver and upregulating LDL receptors, enhancing clearance of circulating LDL.
Indications:
- Secondary prevention of cardiovascular and cerebrovascular events
- Post-myocardial infarction or post-angioplasty/stenting
- Established atherosclerotic cardiovascular disease
- Patients with high LDL cholesterol and risk of thrombosis
- Stable angina, stroke prevention, and peripheral artery disease
